Platinum Investment Management LTD Biocryst Pharmaceuticals Inc Transaction History

Platinum Investment Management LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$10.5 - $14.2 $910,455 - $1.23 Million	-86,710 Reduced 39.11%	134,989 $1.55 Million
Q4 2021 Feb 11, 2022	BUY	$11.18 - $15.46 $1.03 Million - $1.42 Million	92,011 Added 70.95%	221,699 $3.07 Million
Q3 2021 Nov 09, 2021	SELL	$14.21 - $17.65 $554,573 - $688,826	-39,027 Reduced 23.13%	129,688 $1.86 Million
Q1 2021 May 13, 2021	SELL	$7.37 - $13.61 $2.13 Million - $3.94 Million	-289,360 Reduced 63.17%	168,715 $1.72 Million
Q4 2020 Feb 12, 2021	SELL	$3.37 - $8.61 $14,581 - $37,255	-4,327 Reduced 0.94%	458,075 $3.41 Million
Q2 2020 Aug 06, 2020	SELL	$1.9 - $5.61 $587,069 - $1.73 Million	-308,984 Reduced 40.06%	462,402 $2.2 Million
Q1 2020 May 15, 2020	BUY	$1.6 - $4.11 $1.23 Million - $3.17 Million	771,386 New	771,386 $1.54 Million

279

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Platinum Investment Management LTD, based on Form 13F filings with the SEC.

Stay updated on Platinum Investment Management LTD with notifications on news.